#1 Clinical Trials Search in Europe

Adeno-Associated Viral Vector Serotype 2/8 Containing The Human Ugt1A1 Gene

Recent clinical trials are investigating the use of an innovative gene therapy, Adeno-Associated Viral Vector Serotype 2/8 Containing The Human UGT1A1 Gene (GNT0003), for patients with severe Crigler-Najjar syndrome. This rare genetic disorder affects the liver’s ability to process bilirubin, leading to potentially severe complications. The trials aim to evaluate the safety, efficacy, and long-term impact of this groundbreaking treatment approach, offering hope for patients who currently rely on daily phototherapy.

Table of Contents

What is GNT0003?

GNT0003, also known as rAAV8-hUGT1A1, is a promising gene therapy medication designed to treat severe Crigler-Najjar syndrome. It is classified as an adeno-associated viral vector serotype 2/8 containing the human UGT1A1 gene[1]. This innovative treatment is currently being studied in clinical trials to evaluate its safety and effectiveness in patients with Crigler-Najjar syndrome who require daily phototherapy.

How Does GNT0003 Work?

GNT0003 works by using a modified virus (adeno-associated virus) as a carrier to deliver a healthy copy of the UGT1A1 gene to liver cells. The UGT1A1 gene is responsible for producing an enzyme that helps break down bilirubin in the body. In patients with Crigler-Najjar syndrome, this gene is faulty, leading to a buildup of bilirubin in the blood.

When GNT0003 is administered through an intravenous infusion, it aims to restore the expression of the UGT1A1 enzyme in liver cells (hepatocytes). This should allow for the restoration of bilirubin glucuronidation, the process by which bilirubin is made water-soluble and can be eliminated from the body[1].

Treating Crigler-Najjar Syndrome

Crigler-Najjar syndrome is a rare genetic disorder characterized by high levels of bilirubin in the blood (hyperbilirubinemia). Patients with severe Crigler-Najjar syndrome typically require daily phototherapy for extended periods (≥ 6 hours/day) to manage their condition[1]. GNT0003 is being developed as a potential one-time treatment that could significantly reduce or eliminate the need for phototherapy in these patients.

Clinical Trials and Research

GNT0003 is currently being studied in clinical trials to assess its safety and efficacy. Two notable trials are:

  1. A Phase I/II open-label study (CareCN) evaluating the safety and efficacy of a single intravenous injection of GNT0003 in patients with severe Crigler-Najjar syndrome requiring phototherapy[1].

  2. A Phase 2 open-label trial assessing the efficacy and safety of GNT0003 following imlifidase pre-treatment in adult participants with severe Crigler-Najjar syndrome who have pre-existing anti-AAV8 antibodies[2].

These trials aim to determine the optimal dose of GNT0003 and evaluate its effectiveness in reducing bilirubin levels without the need for phototherapy.

Safety and Side Effects

The safety profile of GNT0003 is being closely monitored in clinical trials. Researchers are tracking:

  • Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
  • Changes in laboratory parameters, vital signs, and physical examinations
  • Long-term safety, including the potential for malignancies

As with any gene therapy, there may be risks associated with the treatment. Patients considering GNT0003 should discuss potential side effects and safety concerns with their healthcare providers[1][2].

Potential Benefits

If successful, GNT0003 could offer several benefits to patients with severe Crigler-Najjar syndrome:

  • Reduction or elimination of the need for daily phototherapy
  • Improved quality of life, including better sleep patterns
  • Decreased risk of bilirubin-induced neurological damage
  • Potential long-term correction of the genetic defect

Researchers are measuring these outcomes through various means, including changes in total bilirubin levels, bilirubin/albumin ratios, and quality of life questionnaires[1][2].

Eligibility for Treatment

While GNT0003 is still in clinical trials, eligibility criteria for participants typically include:

  • Confirmed diagnosis of severe Crigler-Najjar syndrome requiring daily phototherapy
  • Molecular confirmation of mutations in the UGT1A1 gene
  • No history of liver transplantation
  • Absence of significant liver fibrosis or other serious medical conditions

Specific eligibility criteria may vary between different clinical trials and may change as research progresses[1][2].

Future Prospects

GNT0003 represents a promising advancement in the treatment of Crigler-Najjar syndrome. If clinical trials demonstrate its safety and efficacy, it could potentially offer a one-time treatment option for patients who currently rely on lifelong phototherapy. The ongoing research also explores the use of pre-treatment with imlifidase to potentially expand the eligible patient population to include those with pre-existing antibodies against the viral vector[2].

As research continues, more information about the long-term effects and durability of GNT0003 treatment will become available, potentially paving the way for its approval and wider use in treating Crigler-Najjar syndrome.

Aspect Details
Treatment GNT0003 (Adeno-Associated Viral Vector Serotype 2/8 Containing The Human UGT1A1 Gene)
Administration Single intravenous infusion
Target Condition Severe Crigler-Najjar syndrome requiring daily phototherapy
Primary Objective Assess safety, tolerability, and efficacy in reducing serum bilirubin levels
Key Efficacy Measure Proportion of patients with serum total bilirubin ≤ 300 µmol/L at Week 48 without phototherapy from Week 16
Safety Assessments Adverse events, laboratory parameters, vital signs, physical examinations
Secondary Objectives Pharmacokinetics, pharmacodynamics, quality of life impact
Follow-up Duration Up to 48 weeks for primary endpoints, with some studies extending to 60 months
Special Considerations Some trials include imlifidase pre-treatment for patients with pre-existing anti-AAV8 antibodies

FAQ

  • What is Crigler-Najjar syndrome? Crigler-Najjar syndrome is a rare genetic disorder that affects the liver's ability to process bilirubin, a yellow substance produced when red blood cells break down. People with severe Crigler-Najjar syndrome require daily phototherapy to manage their condition and prevent complications.
  • How does the gene therapy (GNT0003) work? GNT0003 is an adeno-associated viral vector that carries the human UGT1A1 gene. When administered intravenously, it aims to restore the expression of the UGT1A1 enzyme in liver cells. This should allow for the restoration of bilirubin glucuronidation, potentially reducing the need for phototherapy.
  • Who is eligible for these clinical trials? The trials are primarily for patients with severe Crigler-Najjar syndrome requiring daily phototherapy (6 hours or more per day). Participants must have confirmed mutations in the UGT1A1 gene. Some trials focus on adults, while others may include younger patients. Specific eligibility criteria vary between studies.
  • What are the main objectives of these clinical trials? The main objectives include assessing the safety and efficacy of GNT0003, evaluating its impact on reducing serum bilirubin levels, determining if patients can reduce or eliminate phototherapy, and measuring improvements in quality of life. The trials also aim to study the pharmacokinetics and long-term effects of the treatment.
  • How long do these clinical trials last? The duration of the trials varies, but many include a follow-up period of up to 48 weeks after GNT0003 administration. Some studies also plan for longer-term monitoring, up to 60 months, to assess long-term safety and efficacy.

Ongoing Clinical Trials on Adeno-Associated Viral Vector Serotype 2/8 Containing The Human Ugt1A1 Gene

  • Study of GNT0003 and imlifidase in adults with Crigler-Najjar syndrome who require daily phototherapy and have pre-existing AAV8 antibodies

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Gene Therapy GNT0003 for Patients with Severe Crigler-Najjar Syndrome Requiring Phototherapy

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy The Netherlands

Glossary

  • Crigler-Najjar syndrome: A rare genetic disorder affecting the liver's ability to process bilirubin, leading to high levels of bilirubin in the blood which can cause severe complications if left untreated.
  • Bilirubin: A yellow substance produced when red blood cells break down. High levels can be toxic and cause jaundice and other complications.
  • UGT1A1 gene: A gene that provides instructions for making an enzyme involved in processing bilirubin in the liver. Mutations in this gene cause Crigler-Najjar syndrome.
  • Phototherapy: A treatment using special lights to help break down bilirubin in the skin. Patients with severe Crigler-Najjar syndrome often require daily phototherapy.
  • Adeno-Associated Viral Vector: A modified virus used to deliver genetic material into cells. In this case, it's used to carry the UGT1A1 gene into liver cells.
  • Gene therapy: A technique that uses genes to treat or prevent disease. In this context, it involves introducing a functional UGT1A1 gene to compensate for the mutated gene.
  • Intravenous infusion: A method of delivering medications or fluids directly into a vein using a needle or tube.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. http://clinicaltrials.eu/trial/study-on-gene-therapy-gnt0003-for-patients-with-severe-crigler-najjar-syndrome-requiring-phototherapy/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-gnt0003-and-imlifidase-for-adults-with-severe-crigler-najjar-syndrome-and-anti-aav8-antibodies/